Weight reduction by mazindol in morbid obesity with or without type 2 diabetes mellitus

Weight reduction by mazindol in morbid obesity with or without type 2 diabetes mellitus - Weight reduction by mazindol in morbid obesity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027557

Enrollment

Registered

2017-08-01

Start date

2017-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity disease

Interventions

administration of mazindol: 0.5mg/day for 2 weeks, followed by 1mg/day for 2 weeks and 1.5mg/day for 2 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: morbid obesity(BMI:35 or more)

Exclusion criteria

Exclusion criteria: Patients with contraindication for administration of mazindol or SGLT2 inhibitor

Design outcomes

Primary

Measure	Time frame
Weight reduction rate in 3 months' administration of mazindol, with or without the use of SGLT2 inhibitor	—

Countries

Japan

Contacts

Public ContactMakito Tanabe

Fukuoka University Hospital Department of Endocrinology and Diabetes Mellitus

mtanabe@live.jp092-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026